Laurion Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-126,900
Closed -$1.24M 1068
2019
Q4
$1.24M Buy
+126,900
New +$1.13M 0.01% 532
2019
Q3
Sell
-250,000
Closed -$2.31M 1279
2019
Q2
$2.31M Buy
+250,000
New +$3.01M 0.02% 361
2019
Q1
Sell
-80,000
Closed -$1.23M 1277
2018
Q4
$1.23M Hold
80,000
0.02% 508
2018
Q3
$1.72M Hold
80,000
0.02% 570
2018
Q2
$1.95M Hold
80,000
0.02% 610
2018
Q1
$1.37M Sell
80,000
-667,500
-89% -$13M 0.01% 747
2017
Q4
$14.2M Sell
747,500
-153,000
-17% -$2.3M 0.07% 272
2017
Q3
$15.8M Buy
900,500
+733,000
+438% +$16.5M 0.07% 219
2017
Q2
$5.57M Hold
167,500
0.03% 473
2017
Q1
$5.38M Buy
167,500
+125,000
+294% +$4.27M 0.04% 403
2016
Q4
$1.54M Sell
42,500
-410,600
-91% -$16.4M 0.01% 637
2016
Q3
$20.8M Buy
453,100
+373,500
+469% +$19.5M 0.2% 116
2016
Q2
$4M Sell
79,600
-180,400
-69% -$9.6M 0.06% 303
2016
Q1
$13.9M Buy
260,000
+100,000
+63% +$5.87M 0.22% 114
2015
Q4
$10.5M Buy
+160,000
New +$9.89M 0.1% 213
2014
Q3
Sell
-200,000
Closed -$10.5M 391
2014
Q2
$10.5M Buy
+200,000
New +$10.2M 0.22% 133

Other funds holding TEVA

Laurion Capital Management's TEVA Position: Q4 2020 in Review

Laurion Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2020, closing a stake of 116,600 shares — an estimated $1.05M sold.

Laurion Capital Management first reported a position in TEVA in Q3 2015 and held it in 16 quarters. The position peaked at $40.8M in Q3 2016. 450 funds tracked by Wall St. Rank hold TEVA as of Q4 2020.

  • Laurion Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Laurion Capital Management sold 116,600 Teva Pharmaceuticals shares in Q4 2020, an estimated $1.05M.
  • Laurion Capital Management first reported a position in Teva Pharmaceuticals in Q3 2015 and held it in 16 quarters.
  • Laurion Capital Management's Teva Pharmaceuticals position peaked at $40.8M in Q3 2016.
  • 450 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2020.

Based on Laurion Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.